Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial.

CONTEXT The effectiveness of recruiting local medical opinion leaders to improve quality of care is poorly understood. OBJECTIVE To evaluate a guideline-implementation intervention of clinician education by local opinion leaders and performance feedback to (1) increase use of lifesaving drugs (aspirin and thrombolytics in eligible elderly patients, beta-blockers in all eligible patients) for acute myocardial infarction (AMI), and (2) decrease use of a potentially harmful therapy (prophylactic lidocaine). DESIGN Randomized controlled trial with hospital as the unit of randomization, intervention, and analysis. SETTING Thirty-seven community hospitals in Minnesota. PATIENTS All patients with AMI admitted to study hospitals over 10 months before (1992-1993, N=2409) or after (1995-1996, N=2938) the intervention. INTERVENTION Using a validated survey, we identified opinion leaders at 20 experimental hospitals who influenced peers through small and large group discussions, informal consultations, and revisions of protocols and clinical pathways. They focused on (1) evidence (drug efficacy), (2) comparative performance, and (3) barriers to change. Control hospitals received mailed performance feedback. MAIN OUTCOME MEASURES Hospital-specific changes before and after the intervention in the proportion of eligible patients receiving each study drug. RESULTS Among experimental hospitals, the median change in the proportion of eligible elderly patients receiving aspirin was +0.13 (17% increase from 0.77 at baseline), compared with a change of -0.03 at control hospitals (P=.04). For beta-blockers, the respective changes were +0.31 (63% increase from 0.49 at baseline) vs +0.18 (30% increase from baseline) for controls (P=.02). Lidocaine use declined by about 50% in both groups. The intervention did not increase thrombolysis in the elderly (from 0.73 at baseline), but nearly two thirds of eligible nonrecipients were older than 85 years, had severe comorbidities, or presented after at least 6 hours. CONCLUSIONS Working with opinion leaders and providing performance feedback can accelerate adoption of some beneficial AMI therapies (eg, aspirin, beta-blockers). Secular changes in knowledge and hospital protocols may extinguish outdated practices (eg, prophylactic lidocaine). However, it is more difficult to increase use of effective but riskier treatments (eg, thrombolysis) for frail elderly patients.

[1]  ISIS-1 Collaborative Group RANDOMISED TRIAL OF INTRAVENOUS ATENOLOL AMONG 16 027 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-1 , 1986, The Lancet.

[2]  D. Berwick Quality of health care. Part 5: Payment by capitation and the quality of care. , 1996, The New England journal of medicine.

[3]  G. Bole,et al.  Evaluation of a continuing education program in rheumatoid arthritis. , 1980, Arthritis and rheumatism.

[4]  S B Soumerai,et al.  Efficacy and cost-containment in hospital pharmacotherapy: state of the art and future directions. , 1984, The Milbank Memorial Fund quarterly. Health and society.

[5]  S Greenfield,et al.  The Importance of Co-existent Disease in the Occurrence of Postoperative Complications and One-Year Recovery in Patients Undergoing Total Hip Replacement: Comorbidity and Outcomes After Hip Replacement , 1993, Medical care.

[6]  J. Eisenberg,et al.  Changing physicians' practices. , 1993, Tobacco control.

[7]  N. Laird,et al.  Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction. , 1989, Archives of internal medicine.

[8]  R. Hiss,et al.  Continuing education in pulmonary disease for primary-care physicians. , 2015, The American review of respiratory disease.

[9]  S B Soumerai,et al.  Principles of educational outreach ('academic detailing') to improve clinical decision making. , 1990, JAMA.

[10]  J. Gurwitz,et al.  Consultation between cardiologists and generalists in the management of acute myocardial infarction: implications for quality of care. , 1998, Archives of internal medicine.

[11]  J. Gurwitz,et al.  Coronary thrombolysis for the elderly? , 1991, JAMA.

[12]  F. Klocke,et al.  Guidelines for the early management of patients with acute myocardial infarction , 1990 .

[13]  E. McGlynn,et al.  Measuring Quality of Care , 1996 .

[14]  Richard P. Lewis,et al.  ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[15]  J. Kassirer,et al.  Quality and the medical marketplace--following elephants. , 1996, The New England journal of medicine.

[16]  Eugene Vayda,et al.  Opinion leaders vs audit and feedback to implement practice guidelines. Delivery after previous cesarean section. , 1991, JAMA.

[17]  J. Gurwitz,et al.  Delayed Hospital Presentation in Patients Who Have Had Acute Myocardial Infarction , 1997, Annals of Internal Medicine.

[18]  Elizabeth C. Hirschman,et al.  Judgment under Uncertainty: Heuristics and Biases , 1974, Science.

[19]  S. Yusuf,et al.  Routine medical management of acute myocardial infarction. Lessons from overviews of recent randomized controlled trials. , 1990, Circulation.

[20]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[21]  B. McNeil,et al.  Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. , 1994, Journal of the American College of Cardiology.

[22]  Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. , 1997, JAMA.

[23]  A D Oxman,et al.  Changing physician performance. A systematic review of the effect of continuing medical education strategies. , 1995, JAMA.

[24]  A L Greer,et al.  The State of the Art Versus the State of the Science: The Diffusion of New Medical Technologies into Practice , 1988, International Journal of Technology Assessment in Health Care.

[25]  E. Antman,et al.  Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. , 1996, Archives of internal medicine.

[26]  H. Krumholz,et al.  Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. , 1995, JAMA.

[27]  R. Collins,et al.  Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. , 1997, The New England journal of medicine.

[28]  M. Chassin Quality of health care. Part 3: improving the quality of care. , 1996, The New England journal of medicine.

[29]  J. Gurwitz,et al.  Controversies Surrounding the Use of β-Blockers in Older Patients with Cardiovascular Disease , 1994, Drugs & aging.

[30]  D Blumenthal,et al.  Quality of health care. Part 4: The origins of the quality-of-care debate. , 1996, The New England journal of medicine.

[31]  J. Avorn,et al.  Improving drug prescribing in primary care: a critical analysis of the experimental literature. , 1989, The Milbank quarterly.

[32]  J Lomas,et al.  Evaluating the Message: The Relationship Between Compliance Rate and the Subject of a Practice Guideline , 1994, Medical care.

[33]  J. Gurwitz,et al.  Coronary thrombolysis for the elderly. Is clinical practice really lagging behind evidence of benefit? , 1997, JAMA.

[34]  R. Holman,et al.  Cost-effectiveness analysis of a rotavirus immunization program for the United States. , 1995, JAMA.

[35]  Dwight Lemon,et al.  Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 , 1987 .